Antimicrobial Agents and Chemotherapy · 1991 · 51 citations · 12 references
PharmacyPharmacokineticsPharmacologyAntimicrobial PharmacotherapyBioavailabilityOral Drug DeliveryAntibacterial PharmacologyAntibacterial PharmacotherapyAntibacterial TherapyBacterial InfectionsPulmonary InfectionsRespiratory InfectionsBacterial Pneumonia TreatmentIn Vivo StudiesOral Antibiotic ProphylaxisPneumococcal Pneumonia TreatmentPneumonia Antibiotic TherapySingle-dose ProphylaxisStreptococcus SpeciesSurvival Rates
Azithromycin is a new acid-stable 15-membered-ring macrolide that exhibits an extended half-life and excellent tissue distribution, including distribution in the lung. We compared its in vivo activity with that of erythromycin using two models of Streptococcus pneumoniae pneumonia, namely, a model of acute infection in Swiss mice and a model of subacute infection in C57BL/6j mice. Female mice were infected by oral delivery into the trachea of 10(5) CFU of a virulent serotype 3 strain of S. pneumoniae (P 4241). Prophylactic and therapeutic treatments were given orally (p.o.) or subcutaneously (s.c.) by various regimens. In the model of subacute infection, a single dose of azithromycin, 25 mg/kg, given p.o. 7 h before infection protected 92% of the mice, while erythromycin was completely ineffective. In the model of acute infection, a single dose of azithromycin, 50 mg/kg, given s.c. 24 h prior to challenge protected 80% of the mice, whereas only 35% of the mice survived with erythromycin, 50 mg/kg, 1 h before challenge. Therapy, which was studied exclusively in the model of subacute infection, was initiated 48 h postinfection. Two doses of 12.5 mg/kg given p.o. 12 h apart resulted in 80% survival of mice treated with azithromycin versus 7% survival of mice treated with erythromycin. Pulmonary clearance of bacteria was consistent with the survival rates. Two doses (25 mg/kg) of azithromycin given s.c. at 48 and 65 h after infection led to complete clearance of bacteria from the lungs and blood, whereas erythromycin-treated mice remained bacteremic. The pharmacokinetics of azithromycin account for its superior efficacy against S. pneumoniae pneumonia relative to the efficacy of erythromycin.
12
PROSPECTIVE STUDY OF THE AETIOLOGY AND OUTCOME OF PNEUMONIA IN THE COMMUNITY
Mark Woodhead, J T Macfarlane, John McCracken et al. · The Lancet · 1987 · 595 citations
Ronald P. Gladue, G. Michael Bright, Richard E. Isaacson et al. · Antimicrobial Agents and Chemotherapy · 1989 · 476 citations
Medicine, Immunology, Pharmacology +14
James A. Retsema, Agnès Girard, W Schelkly et al. · Antimicrobial Agents and Chemotherapy · 1987 · 461 citations
David J. Greenblatt, Jan Koch‐Weser · New England Journal of Medicine · 1975 · 434 citations